REGN Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals (NASDAQ:REGN) and Sanofi said they are expanding their long-running collaboration to develop and commercialize next-generation medicines for type 2 inflammatory diseases, adding four Regeneron-originated antibody programs and establishing a new equal-sharing economic framew

The companies will share development and commercialization costs as well as potential future profits from the new drugs, they said.

Exxon Mobil downgraded, BP upgraded: Wall Street's top analyst calls

The companies will share development and commercialization costs as well as potential future profits from the new drugs, they said.

Investing.com -- Sanofi SA (EPA:SASY) will pay Regeneron $1 billion upfront and up to $7 billion in additional payments to expand their partnership on four new long-acting medicines for inflammatory diseases, as the French drugmaker looks to build its pipeline beyond its blockbuster Dupixent treatment.

Kodiak Sciences tripled in a single session after its eye drug cleared a pivotal trial, but a cash-burning biotech with no revenue and a likely share offering complicates any case for chasing the move.

Citi downgraded Moderna to 'Sell' on valuation concerns after a massive 2026 rally, while investors await detailed Phase 3 melanoma data at ESMO next month.

REGN vs. ILMN: Which Stock Is the Better Value Option?

Kodiak surges 178% as positive phase III DAYBREAK data show Zenkuda and tabirafusp-ted met key endpoints against Eylea.

MIRM's brelovitug meets the phase III AZURE-1 goal in chronic hepatitis delta virus, with strong virologic response and ALT normalization rates.

GSK and Sanofi offer distinct growth drivers, but stronger earnings estimates, Dupixent momentum and a lower valuation are putting one European drugmaker in focus.

Regeneron Pharmaceuticals (REGN) is back in focus after Biohaven entered a new clinical supply agreement to pair BHV-1530 with Regeneron’s cancer drug Libtayo in patients with solid tumors, with enrollment in the combination cohort already underway. Despite today’s pullback, with the share price down 4.54% over the past day to US$752.25 and weaker recent momentum, Regeneron Pharmaceuticals still carries a 90 day share price return of 20.64% and a 1 year total shareholder return of 34.84%...

Regeneron Pharmaceuticals (NasdaqGS: REGN) faces fresh pressure after Kodiak Sciences reported new Phase 3 data on its eye drugs. Kodiak said Zenkuda and tabirafusp alfa tedromer matched Eylea on primary Phase 3 endpoints for macular degeneration treatment. The trial reported similar vision outcomes with Kodiak's candidates given roughly every six months versus Eylea's current eight week dosing interval. This comparison between Eylea and Kodiak's longer interval injections is only one piece...

Its latest study suggested its drug candidates improved eyesight for patients with wet macular degeneration as much as the leading treatment.

Martin Shkreli, who said he was short KOD before the readout, questioned Zenkuda’s edge over Eylea and dismissed the added IL-6 targeting in KSI-501.

The healthcare company will release its third-quarter results next month.

OCUL’s selloff on Monday was spurred by clinical updates from competitors on their wet AMD treatments.

The Phase 3 findings suggested Kodiak might have multiple threats to Regeneron’s Eylea and added more than $3 billion to the company’s market value.

If approved, Zenkuda will compete with blockbuster wAMD sellers like Eylea and Vabysmo.

While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies — as Jeff Bezos said, “Your margin is my opportunity”.

Kodiak Sciences stock skyrocketed Monday on a double win for its potential rivals to Regeneron Pharmaceuticals' blockbuster eye drug, Eylea.

Kodiak Sciences plans to file for regulatory approval of one drug candidate, Zenkuda, following its success in a trial for wet age-related macular degeneration.

SNY's new drugs are gaining momentum, with Altuviiio, Ayvakit and Sarclisa poised to broaden growth beyond Dupixent.

Regeneron Pharmaceuticals has delivered a strong share price run over the past year, which puts a spotlight on whether the current US$801.82 level is still grounded in what the business earns today. With the focus squarely on profits and the P/E discussion around them, the question is how much of that recent strength can be explained by earnings power rather than sentiment alone. The stock has returned 39.7% over the past year. This puts real pressure on the valuation case to be supported by...

Regeneron Pharmaceuticals (NASDAQ:REGN) executives highlighted continued growth across key marketed products, a broad late-stage pipeline and an ongoing focus on science-driven business development during a discussion with Bernstein analyst Jeffrey Walch. Chris Fenimore, Regeneron’s executive vice

The past couple of years have been challenging for the company, but there is a light at the end of the tunnel.

Sanofi (NASDAQ:SNY) is reviewing its late-stage pipeline, broadening its business-development lens and working to rebuild early research output under new leadership, Chief Scientific Officer and Global Head of Research Mike Quigley said at a Bank of America event. Quigley said Chief Executive Offic

The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning. Some companies face significant challenges, whether it’s stagnating growth, heavy debt, or disruptive new competitors.

Telix Pharmaceuticals (TLX) agreed to acquire Germany-based ITM Isotope Technologies Munich in a dea

Sanofi (NASDAQ:SNY) is prioritizing continued growth in Specialty Care while preparing for the loss of exclusivity of Dupixent in the early part of the next decade, according to Manuela Buxo, the company’s executive vice president and head of Specialty Care. Speaking at a Morgan Stanley fireside ch

NTLA wins FDA priority review for lonvo-z, with a March 10, 2027 decision, potentially adding its first product, while nex-z studies are progressing well.

The biotech company’s stock rises after Barclays gives it a double upgrade, citing confidence in upcoming FDA approvals.

Barclays analyst Glen Santangelo raised the stock to Overweight from Underweight and lifted his target to $8 from $4.

In September 2026, several law firms, including Bronstein, Gewirtz & Grossman and Robbins Geller Rudman & Dowd, filed federal securities class action lawsuits against Regeneron Pharmaceuticals, alleging that management misled investors about key design assumptions and clinical prospects for its Phase III Fianlimab-Libtayo oncology trial. The complaints center on claims that Regeneron understated the risk that Fianlimab-Libtayo would fail to show meaningful benefit over standard therapies,...

Novo Nordisk is bigger and more profitable on paper, but pricing pressure, reduced Medicaid coverage, and intensifying competition are creating headwinds that Regeneron simply does not face right now.

Regeneron Pharmaceuticals (REGN) is back in focus after law firm Bronstein, Gewirtz & Grossman announced a securities class action tied to disclosures around the Phase III Fianlimab Libtayo trial. Recent trading tells a mixed story for Regeneron Pharmaceuticals. The share price is up 29.12% over the past 90 days and the 1 year total shareholder return is 39.33%, even though the 7 day share price return is down 4.11% as investors weigh the lawsuit headlines against a longer trend of positive...

Regeneron Pharmaceuticals (NASDAQ:REGN) outlined growth opportunities for Dupixent, pipeline catalysts for cemdisiran and continued commercial momentum for EYLEA HD during the Morgan Stanley Global Healthcare Conference. Marion McCourt, Regeneron’s EVP and head of commercial, said Dupixent’s growth

Regeneron Pharmaceuticals (NASDAQ:REGN) executives outlined plans for continued growth across its commercial portfolio, upcoming regulatory milestones and pipeline programs during a Wells Fargo investor conference appearance. Ryan Crowe, senior vice president of investor relations and strategic ana

American Century Investments, an investment management company, released its first-quarter 2026 investor letter for the “American Century Investments Focused Dynamic Growth Fund”. The letter can be downloaded here. U.S. stocks advanced sharply with double-digit quarterly gains largely due to robust earnings, resilient economic data, and momentum in AI-related stocks. However, there was a slight pullback […]

NTLA's BLA for lonvo-z wins FDA priority review for the treatment of HAE. A decision from the agency is expected by March 10, 2027.

Harbor Funds, an investment management company, released its Q2 2026 investor letter for “Harbor Mid Cap Value Fund”. The letter can be downloaded here. Global equities experienced a sharp rally in Q2 2026, with the S&P 500 returning 15.2%, its strongest quarter since 2020, driven by a shift from software to hardware in the Artificial Intelligence […]

While Wall Street piles into AI darlings, Michael Burry is quietly loading up on call options in three stocks the market left for dead, and his biggest bets carry a very specific thesis about where the crowd got it wrong.

Although Regeneron (currently trading at $845.04 per share) has gained 8.1% over the last six months, it has trailed the S&P 500’s 13.6% return during that period. This may have investors wondering how to approach the situation.

Biotech just staged one of its sharpest reversals in years, and whether you caught it or completely missed it, the same uncomfortable question now sits in front of every portfolio: does the trade still have teeth, or did the easy money already leave?

They could both outperform the market over the medium term, but one appears to have a clear edge.

Black Diamond (BDTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

The drugmaker is leaning on a better side effect profile compared to drugs from J&J, Pfizer and Regeneron as it pushes etentamig toward FDA submission.

Veeva Systems (NYSE: VEEV) announced that Regeneron and Biogen have adopted its AI powered Vault CRM suite globally. The company also introduced Veeva Falcon Safety, a new agentic safety operations product for biopharma clients. Both moves expand Veeva Systems' AI focused offering across commercial and safety workflows in life sciences. These updates highlight how AI heavy software is becoming core infrastructure for healthcare and biopharma workflows. This connects directly to a wider set...

Regeneron Pharmaceuticals has outpaced the healthcare sector, and analysts remain moderately optimistic about the stock’s outlook.

Regeneron Pharmaceuticals (REGN) is back in focus after the FDA approved Pasatru garetosmab grts for adults with fibrodysplasia ossificans progressiva, following positive Phase 3 OPTIMA trial data on heterotopic ossification lesion reduction. Regeneron Pharmaceuticals shares trade at US$794.19 after a recent pullback, with the 7 day share price return down 4.78% and the 90 day share price return up 32.22%. The 1 year total shareholder return of 37.47% points to momentum that has built over a...